Regulatory News Item

RNS Number : 4369P

Smiths Group PLC

29 May 2018

News Release

London, 27 May 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Sunday 27 May 2018

Smiths Group plc ("Smiths")

Statement regarding Smiths Medical

Smiths notes the press speculation regarding discussions involving its Smiths Medical business and confirms that it is in very early stage discussions about a potential combination of its medical division with ICU Medical, Inc. (NASDAQ: ICUI).

The Board of Smiths routinely reviews all options for the Group's portfolio of businesses to maximise value for Smiths shareholders.

There can be no certainty that a transaction will be concluded.

END

Contact details
Investor enquiries
Jemma Spalton, Smiths Group +44 (0)20 7004 1637 +44 (0)78 6739 0350 jemma.spalton@smiths.com	Marion Le Bot, Smiths Group +44 (0)20 7004 1672 +44 (0)75 8315 4386 marion.lebot@smiths.com
Media enquiries
Deborah Scott, FTI Consulting +44 (0)20 3727 1459 +44 (0)797 953 7449 smiths@fticonsulting.com	Alex Le May, FTI Consulting +44 (0)20 3727 1308 +44 (0)7702 443 312 smiths@fticonsulting.com

About Smiths Group

Smiths Group is a global technology company listed on the London Stock Exchange (SMIN) and operates a sponsored level one ADR programme (SMGZY). A world leader in the practical application of advanced technologies, Smiths Group delivers products and services for the medical technology, security & defence, general industrial, oil & gas, and space & aerospace markets worldwide. Smiths Group employs c.22,000 colleagues in over 50 countries. For more information visit www.smiths.com.

About Smiths Medical

Smiths Medical is a leading supplier of specialised medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information visit www.smiths-medical.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

STRAPMLTMBJTBMP